Panbela Therapeutics, Inc. (PBLA)
Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Panbela Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 4.85M shares outstanding
USPanbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients.
The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.
Leadership
Arthur J. Fratamico
Director
D. Robert Schemel
Director
Daniel J. Donovan
Director
Jeffrey E. Jacob
Director
Employees
8
Country
US
Sector
Healthcare
Website
panbela.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Nant Capital, LLC | 10% Owner | Purchase | 0 | -- | Nov 15, 2024 |
 Horvath Susan | V.P. of Finance & CFO | Grant/Award | 25.5K | -- | Oct 1, 2024 |
 Simpson Jennifer K. | President and CEO | Grant/Award | 72.8K | -- | Oct 1, 2024 |
Insiders
- Nant Capital, LLC10% Owner
- Horvath SusanV.P. of Finance & CFO
- Simpson Jennifer K.President and CEO
based on 4.85M shares outstanding
US30d Avg
6.32K
60d Avg
4.08K
90d Avg
3.46K